PURPOSE: To assess the dependence of neovascular molecular magnetic resonance (MR) imaging on relaxivity (r1) of αvβ3-targeted paramagnetic perfluorocarbon (PFC) nanoparticles and to delineate the temporal-spatial consistency of angiogenesis assessments for individual animals. MATERIALS AND METHODS: Animal protocols were approved by the Washington University Animal Studies Committee. Proton longitudinal and transverse relaxation rates of αvβ3-targeted and nontargeted PFC nanoparticles incorporating gadolinium diethylenetrianime pentaacedic acid (Gd-DTPA) bisoleate (BOA) or gadolinium tetraazacyclododecane tetraacetic acid (Gd-DOTA) phosphatidylethanolamine (PE) into the surfactant were measured at 3.0 T. These paramagnetic nanoparticles were compared in 30 New Zealand White rabbits (four to six rabbits per group) 14 days after implantation of a Vx2 tumor. Subsequently, serial MR (3.0 T) neovascular maps were developed 8, 14, and 16 days after tumor implantation by using αvβ3-targeted Gd-DOTA-PE nanoparticles (n = 4) or nontargeted Gd-DOTA-PE nanoparticles (n = 4). Data were analyzed with analysis of variance and nonparametric statistics. RESULTS: At 3.0 T, Gd-DTPA-BOA nanoparticles had an ionic r1 of 10.3 L · mmol(-1) · sec(-1) and a particulate r1 of 927000 L · mmol(-1) · sec(-1). Gd-DOTA-PE nanoparticles had an ionic r1 of 13.3 L · mmol(-1) · sec(-1) and a particulate r1 of 1 197000 L · mmol(-1) · sec(-1). Neovascular contrast enhancement in Vx2 tumors (at 14 days) was 5.4% ± 1.06 of the surface volume with αvβ3-targeted Gd-DOTA-PE nanoparticles and 3.0% ± 0.3 with αvβ3-targeted Gd-DTPA-BOA nanoparticles (P = .03). MR neovascular contrast maps of tumors 8, 14, and 16 days after implantation revealed temporally consistent and progressive surface enhancement (1.0% ± 0.3, 4.5% ± 0.9, and 9.3% ± 1.4, respectively; P = .0008), with similar time-dependent changes observed among individual animals. CONCLUSION: Temporal-spatial patterns of angiogenesis for individual animals were followed to monitor longitudinal tumor progression. Neovasculature enhancement was dependent on the relaxivity of the targeted agent.
PURPOSE: To assess the dependence of neovascular molecular magnetic resonance (MR) imaging on relaxivity (r1) of αvβ3-targeted paramagnetic perfluorocarbon (PFC) nanoparticles and to delineate the temporal-spatial consistency of angiogenesis assessments for individual animals. MATERIALS AND METHODS: Animal protocols were approved by the Washington University Animal Studies Committee. Proton longitudinal and transverse relaxation rates of αvβ3-targeted and nontargeted PFC nanoparticles incorporating gadolinium diethylenetrianime pentaacedic acid (Gd-DTPA) bisoleate (BOA) or gadolinium tetraazacyclododecane tetraacetic acid (Gd-DOTA) phosphatidylethanolamine (PE) into the surfactant were measured at 3.0 T. These paramagnetic nanoparticles were compared in 30 New Zealand White rabbits (four to six rabbits per group) 14 days after implantation of a Vx2 tumor. Subsequently, serial MR (3.0 T) neovascular maps were developed 8, 14, and 16 days after tumor implantation by using αvβ3-targeted Gd-DOTA-PE nanoparticles (n = 4) or nontargeted Gd-DOTA-PE nanoparticles (n = 4). Data were analyzed with analysis of variance and nonparametric statistics. RESULTS: At 3.0 T, Gd-DTPA-BOA nanoparticles had an ionic r1 of 10.3 L · mmol(-1) · sec(-1) and a particulate r1 of 927000 L · mmol(-1) · sec(-1). Gd-DOTA-PE nanoparticles had an ionic r1 of 13.3 L · mmol(-1) · sec(-1) and a particulate r1 of 1 197000 L · mmol(-1) · sec(-1). Neovascular contrast enhancement in Vx2 tumors (at 14 days) was 5.4% ± 1.06 of the surface volume with αvβ3-targeted Gd-DOTA-PE nanoparticles and 3.0% ± 0.3 with αvβ3-targeted Gd-DTPA-BOA nanoparticles (P = .03). MR neovascular contrast maps of tumors 8, 14, and 16 days after implantation revealed temporally consistent and progressive surface enhancement (1.0% ± 0.3, 4.5% ± 0.9, and 9.3% ± 1.4, respectively; P = .0008), with similar time-dependent changes observed among individual animals. CONCLUSION: Temporal-spatial patterns of angiogenesis for individual animals were followed to monitor longitudinal tumor progression. Neovasculature enhancement was dependent on the relaxivity of the targeted agent.
Authors: Hui-Fang Zhou; Grace Hu; Samuel A Wickline; Gregory M Lanza; Christine T N Pham Journal: Nanomedicine (Lond) Date: 2010-09 Impact factor: 5.307
Authors: Dushyant V Sahani; Sanjeeva P Kalva; Leena M Hamberg; Peter F Hahn; Christopher G Willett; Sanjay Saini; Peter R Mueller; Ting-Yim Lee Journal: Radiology Date: 2005-03 Impact factor: 11.105
Authors: David F Meoli; Mehran M Sadeghi; Svetlana Krassilnikova; Brian N Bourke; Frank J Giordano; Donald P Dione; Haili Su; D Scott Edwards; Shuang Liu; Thomas D Harris; Joseph A Madri; Barry L Zaret; Albert J Sinusas Journal: J Clin Invest Date: 2004-06 Impact factor: 14.808
Authors: Patrick M Winter; Shelton D Caruthers; Xin Yu; Sheng-Kwei Song; Junjie Chen; Brad Miller; Jeff W M Bulte; J David Robertson; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza Journal: Magn Reson Med Date: 2003-08 Impact factor: 4.668
Authors: Dipanjan Pan; Manojit Pramanik; Angana Senpan; Xinmai Yang; Kwang H Song; Mike J Scott; Huiying Zhang; Patrick J Gaffney; Samuel A Wickline; Lihong V Wang; Gregory M Lanza Journal: Angew Chem Int Ed Engl Date: 2009 Impact factor: 15.336
Authors: Patrick M Winter; Shelton D Caruthers; Andrea Kassner; Thomas D Harris; Lori K Chinen; John S Allen; Elizabeth K Lacy; Huiying Zhang; J David Robertson; Samuel A Wickline; Gregory M Lanza Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Alison K Esser; Anne H Schmieder; Michael H Ross; Jingyu Xiang; Xinming Su; Grace Cui; Huiying Zhang; Xiaoxia Yang; John S Allen; Todd Williams; Samuel A Wickline; Dipanjan Pan; Gregory M Lanza; Katherine N Weilbaecher Journal: Nanomedicine Date: 2015-10-27 Impact factor: 5.307
Authors: Kezheng Wang; Dipanjan Pan; Anne H Schmieder; Angana Senpan; Dennis E Hourcade; Christine T N Pham; Lynne M Mitchell; Shelton D Caruthers; Grace Cui; Samuel A Wickline; Baozhong Shen; Gregory M Lanza Journal: Nanomedicine Date: 2015-01-31 Impact factor: 5.307
Authors: Antonia M Berz; Jessica G Santana; Simon Iseke; Moritz Gross; Vasily Pekurovsky; Fabian Laage Gaupp; Lynn J Savic; Tabea Borde; Luzie A Gottwald; Anne Marie Boustani; Bernhard Gebauer; MingDe Lin; Xuchen Zhang; Todd Schlachter; David C Madoff; Julius Chapiro Journal: J Vasc Interv Radiol Date: 2022-03-26 Impact factor: 3.682
Authors: Christine T N Pham; Dennis G Thomas; Julia Beiser; Lynne M Mitchell; Jennifer L Huang; Angana Senpan; Grace Hu; Mae Gordon; Nathan A Baker; Dipanjan Pan; Gregory M Lanza; Dennis E Hourcade Journal: Nanomedicine Date: 2013-11-08 Impact factor: 5.307
Authors: Dipanjan Pan; Anne H Schmieder; Kezheng Wang; Xiaoxia Yang; Angana Senpan; Grace Cui; Kendall Killgore; Benjamin Kim; John S Allen; Huiying Zhang; Shelton D Caruthers; Baozhong Shen; Samuel A Wickline; Gregory M Lanza Journal: Theranostics Date: 2014-03-11 Impact factor: 11.556